Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Trial Details

NCT ID
NCT06966024
Phase
PHASE1
Sponsor
Deciphera Pharmaceuticals, LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • DCC-2812
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
  • Able to take oral medication
  • If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contrace…
  • Adequate organ function and electrolytes

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →